Wacker’s Secretion Technology Studied

Wacker Biotech (Jena, Germany), a wholly owned subsidiary of Wacker Chemie, says it has completed a feasibility study demonstrating that the company’s secretion technology can produce active protein comparable to that produced by mammalian cell cultures. “We believe the positive results of this study demonstrate that secreting E. coli systems can be a great tool for producing biologics in the future,” says Thomas Maier, managing director of Wacker Biotech. The study was aimed at determining the company’s efficacy of proprietary E. coli...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers